

Jubilant Life Sciences Ltd

Regd. Off: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

Statement of Standalone Unaudited Results for the Quarter ended 30th June,2013

(₹ in Lacs)

Sr. No	Particulars	Quarter Ended			Year Ended
		June 30	March 31	June 30	March 31
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2013	2013	2012	2013
	PART I				
1	Income from operations				
	(a) Net sales/Income from operations (Net of excise duty)	81922	84066	73682	312485
	(b) Other Operating Income	434	488	575	2145
	Total income from operations (net)	82356	84554	74257	314630
2	Expenses				
	a) Cost of materials consumed	41312	41650	35435	152858
	b) Purchase of traded goods	4443	4536	4727	19174
	c) Change in inventories of finished goods, work-in-progress and traded goods	(395)	2018	(1718)	(2417)
	d) Power & fuel	8599	8654	8369	33791
	e) Employee benefits expenses	6646	6867	5608	24865
	f) Depreciation and amortization expenses	4254	4139	3607	15217
	g) Other expenses	10737	12694	9785	40946
	Total expenses	75596	80558	65813	284434
3	Profit/(Loss) from operations before other income, finance cost and exceptional items (1-2)	6760	3996	8444	30196
4	Other Income	201	239	174	892
5	Profit/(Loss) from ordinary activities before finance costs & exceptional items(3+4)	6961	4235	8618	31088
6	Finance costs	4821	4330	4505	17117
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	2140	(95)	4113	13971
8	Exceptional items	12305	2490	10424	15252
9	Profit/(Loss) from ordinary activities before tax (7-8)	(10165)	(2585)	(6311)	(1281)
10	Tax expense (Net)	423	233	1049	3051
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	(10588)	(2818)	(7360)	(4332)
12	Extraordinary items (net of tax expenses)	-	-	-	-
13	Net Profit/(Loss) for the period (11-12)	(10588)	(2818)	(7360)	(4332)
14	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593
15	Reserves (excluding revaluation reserve)				184589
16	Earnings per share of ₹ 1 each before and after extraordinary items (Not annualized)				
	Basic (₹)	(6.65)	(1.77)	(4.62)	(2.72)
	Diluted (₹)	(6.65)	(1.77)	(4.62)	(2.72)
	PART II				
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	- Number of shares (₹ 1 each)	81166083	81166083	81166083	81166083
	- Percentage of shareholding	50.96	50.96	50.96	50.96
2	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	3374000	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	4.32	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	2.12	-
	b) Non-Encumbered				
	- Number of shares	78115056	78115056	74741056	78115056
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	95.68	100.00
	- Percentage of shares (as a % of the total share capital of the company)	49.04	49.04	46.92	49.04
B	Investor Complaints				
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	1			
	Disposed of during the quarter	1			
	Remaining unresolved at the end of the quarter	Nil			



Notes:

1. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 "The Effects of Changes in Foreign Exchange Rates". Accordingly exchange differences amounting to ₹ 2551 lacs for Q1 - FY 2014 has been amortized during the quarter. The accumulated debit balance as on 30th June, 2013 in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) ₹ 11530 lacs, and under Fixed Assets/ Capital Work in Progress ₹ 3672 lacs, is to be amortized over the balance life of loans and assets respectively.
2. The company has applied hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered Accountants of India and the debit balance in hedge reserve(Net) as at 30th June,2013 is ₹ 4270 lacs.
3. During the quarter, the Ministry of Commerce, Republic of China has imposed 24.6 % antidumping duty on pyridine imported from the company for domestic sale in China, on preliminary assessment while the final assessment is under progress. The resultant effect of interim duty has been charged to profit and loss account and adjustment if any, required on final determination will be accounted when such determination is made.
4. Exceptional items include :
 - i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 2551 lacs for Q1 - FY 2014.
 - ii) Mark to Market in respect of Currency & Interest rate swap contracts at the period end resulting in loss/(gain) amounting to ₹ 9322 lacs for Q1- FY 2014 .
 - iii) One time fund raising expenses amounting to ₹ 432 lacs for Q1 - FY 2014.
5. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement.
6. The figures of the last quarter of previous financial year are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the previous financial year.
7. The above un-audited results were , subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 1st August, 2013.

For Jubilant Life Sciences Ltd.



Shyam S Bhartia
Chairman & Managing Director

Place : Noida
Date : 1st August, 2013



Jubilant Life Sciences Ltd.

Standalone Unaudited Segment wise Revenue, Results and Capital Employed for the Quarter ended 30th June,2013

(₹ in Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30	March 31	June 30	March 31
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2013	2013	2012	2013
1	Segment revenue				
	a. Pharmaceuticals	19125	19380	17241	75646
	b. Life Sciences Ingredients	63334	65243	57084	239252
	Total	82459	84623	74325	314898
	Less : Inter segment revenue	103	69	68	268
	Net Sales/Income from operations	82356	84554	74257	314630
	a. Pharmaceuticals	19125	19380	17241	75646
	b. Life Sciences Ingredients	63231	65174	57016	238984
	Total	82356	84554	74257	314630
2	Segment results (profit+)/loss(-) before tax and interest from each segment)				
	a. Pharmaceuticals	4136	1496	4313	15248
	b. Life Sciences Ingredients	6230	6003	7862	24756
	Total	10366	7499	12175	40004
	Less : i Interest(Finance costs)	4821	4330	4505	17117
	ii. Other un-allocable expenditure(including exceptional items)	15911	5993	14155	25060
	iii. Un-allocable Income(including exceptional items)	(201)	(239)	(174)	(892)
	Total Profit/(Loss) before tax	(10165)	(2585)	(6311)	(1281)
3	Capital Employed (Segment assets less Segment liabilities)				
	a. Pharmaceuticals	102190	98684	94961	98684
	b. Life Sciences Ingredients	149717	128987	167253	128987
	Total capital employed in segments	251907	227671	262214	227671
	Add: Un-allocable corporate assets less liabilities	226012	263705	245702	263705
	Total capital employed in the Company	477919	491376	507916	491376



Handwritten signature

K.N. GUTGUTIA & CO.

CHARTERED ACCOUNTANTS

KOLKATA : NEW DELHI

11 K GOPALA TOWER, 25, RAJENDRA PLACE,
NEW DELHI-110008

Office : 25713944, 25788644
Telefax : 25818644

Email : kng1938@vsnl.net
Website : www.cakng.com

**LIMITED REVIEW FOR THE QUARTER ENDED
30th JUNE' 2013**

**TO THE BOARD OF DIRECTORS OF
JUBILANT LIFE SCIENCES LIMITED**

We have reviewed the accompanying Statement of Unaudited Financial Results of **Jubilant Life Sciences Limited** for the quarter ended 30th June, 2013, *except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.* This statement is the responsibility of the Company Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquire of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the aforesaid accompanying Statement of Unaudited Financial Results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", notified pursuant of the Companies (Accounting Standards) Rules, 2006, (as amended), has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR K.N. GUTGUTIA & COMPANY
CHARTERED ACCOUNTANTS
ICAI'S FRN 304153E**

**(B.R. GOYAL)
PARTNER**

M. NO. 12172

Dated: 1st August, 2013

